Holen Sie sich die Stockscreener-App
10.01
1.42%
0.14
Handel nachbörslich:
9.73
-0.28
-2.80%
Schlusskurs vom Vortag:
$9.87
Offen:
$9.95
24-Stunden-Volumen:
1.12M
Relative Volume:
0.58
Marktkapitalisierung:
$733.44M
Einnahmen:
$31,000
Nettoeinkommen (Verlust:
$-54.42M
KGV:
-10.24
EPS:
-0.9778
Netto-Cashflow:
$-48.99M
1W Leistung:
+4.71%
1M Leistung:
-2.82%
6M Leistung:
+71.40%
1J Leistung:
+55.31%
1-Tages-Spanne:
$9.80
$10.13
1-Wochen-Bereich:
$9.1612
$10.20
52-Wochen-Spanne:
$4.35
$11.36
Candel Therapeutics Inc Stock (CADL) Company Profile
Firmenname
Candel Therapeutics Inc
Sektor
Branche
Telefon
617-916-5445
Adresse
117 KENDRICK STREET, NEEDHAM
Compare CADL vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
10.01 | 729.77M | 31,000 | -54.42M | -48.99M | -0.9778 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-10-28 | Eingeleitet | Stephens | Overweight |
| 2025-09-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-06-30 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-02-20 | Eingeleitet | Citigroup | Buy |
| 2025-02-19 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-02-07 | Eingeleitet | BofA Securities | Buy |
| 2022-12-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-08-23 | Eingeleitet | Credit Suisse | Outperform |
| 2021-08-23 | Eingeleitet | Jefferies | Buy |
| 2021-08-23 | Eingeleitet | UBS | Buy |
Alle ansehen
Candel Therapeutics Inc Aktie (CADL) Neueste Nachrichten
Candel Therapeutics Inc (CADL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
BlackRock (CADL holder) discloses 6.6% Candel Therapeutics stake on Schedule 13G - Stock Titan
CADL|Candel Therapeutics Inc|Price:9.560|Chg%:-0.300 - TradingKey
Candel Therapeutics Inc (CADL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Candel Therapeutics Inc (CADL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CADL Stock On Track For Best Day In Nearly 16 Months — What’s Driving The Rally? - Stocktwits
Candel Therapeutics Inc (CADL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Candel Therapeutics Inc (CADL) Balance Sheet - TradingKey
Candel Therapeutics Inc (CADL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Candel Therapeutics Inc (CADL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ETFs Investing in Candel Therapeutics, Inc. Stocks - TradingView
Candel Therapeutics Insider Ups Holding By 14% During Year - simplywall.st
Candel Therapeutics (NASDAQ:CADL) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
Candel Therapeutics Reported Better-Than-Feared Q1 Loss – But All Eyes Turn To This Pivotal Event Tomorrow - Stocktwits
Candel Therapeutics (NASDAQ:CADL) Shares Up 8.1%Here's Why - MarketBeat
CADL Stock Edges Up After Hours On Strong Extended Prostate Cancer Data - Stocktwits
Why CADL Stock Plunged Nearly 15% In After-Hours Trading Today - Stocktwits
Stifel Initiates Candel Therapeutics(CADL.US) With Buy Rating, Announces Target Price $22 - Moomoo
Liquidity Mapping Around (CADL) Price Events - Stock Traders Daily
CADL Initiates Coverage On Candel Therapeutics by Stifel -- Buy Rating Issued - GuruFocus
CADL Q1 2026 Earnings: Narrower Loss Per Share Surpasses Analyst Estimates Amid Ongoing Pipeline DevelopmentDebt Analysis Report - Bölüm Sonu Canavarı
Stifel initiates Candel Therapeutics stock with buy, $22 target By Investing.com - Investing.com Australia
Stifel initiates Candel Therapeutics stock with buy, $22 target - Investing.com UK
Candel Therapeutics (CADL) Short Interest & Short Float | Updated Jul 2026 - MarketBeat
Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)July 8, 2026 - marketscreener.com
Form 4 Candel Therapeutics Inc For: 8 July By Investing.com - Investing.com Nigeria
[Form 4] Candel Therapeutics, Inc. Insider Trading Activity - Stock Titan
Candel Therapeutics (CADL) Chief Commercial Officer Sims listed in Form 3 - Stock Titan
Candel Therapeutics: An Overlooked Late-Stage Biotech With Real Potential - Seeking Alpha
Candel Therapeutics Q1 2026 Earnings: EPS Beats Estimates by 56.68% as Clinical Development AdvancesMargin Expansion Trends - dars.gov.et
Analysts Offer Insights on Healthcare Companies: Candel Therapeutics (CADL) and Ibio (IBIO) - The Globe and Mail
Why (CADL) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Insider Sell: Francesca Barone Sells Shares of Candel Therapeuti - GuruFocus
Candel Therapeutics CSO Francesca Barone sells $235k in stock By Investing.com - Investing.com Australia
Candel Therapeutics CSO Francesca Barone sells $235k in stock - Investing.com
Form 4 Candel Therapeutics Inc For: 1 July By Investing.com - Investing.com UK
Candel Therapeutics (CADL) CSO executes 23,447-share open-market sale under 10b5-1 plan - Stock Titan
Candel Therapeutics (CADL) CTO sells 7,000 shares in planned trade - Stock Titan
Candel Therapeutics (CADL) director receives fully vested grant of 2,199 stock options - Stock Titan
Candel Therapeutics (CADL) director receives fully vested option award - Stock Titan
Finanzdaten der Candel Therapeutics Inc-Aktie (CADL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Candel Therapeutics Inc-Aktie (CADL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Tyagarajan Seshu | Chief Technology Officer |
Jun 29 '26 |
Sale |
10.02 |
7,000 |
70,151 |
83,865 |
2.44%
0.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):